Research teams around the world are looking for a cure for the new coronavirus. As reported by Mirage News , the US is ready to test a drug based on monoclonal antibodies. These elements are designed to provide an immediate antiviral effect that lasts several weeks.
The trials are involving 220 people across the country – the first half will receive a placebo and the other half will receive a drug known as LY3819253. This is an experimental monoclonal antibody therapy developed by Lilly Research Laboratories in partnership with AbCellera Biologics.
Known: AbCellera and the National Institute of Allergy and Infectious Diseases identified antibodies in a blood sample from one of the first people in the United States to recover from COVID-19. Using these antibodies, monoclonal antibodies were generated. These are antibodies produced by immune cells belonging to the same cell clone (derived from a single plasma progenitor cell).
The aim of the new study is to test the safety and antiviral activity of a drug based on monoclonal antibodies. The drug LY3819253 was selected based on data demonstrating its activity against SARS-CoV-2 in laboratory studies, as well as based on pharmacokinetic and safety data of the first phase of trials, which included about 400 people.